Penicillin-binding proteins and Beta-lactamases (PBP/BLI)

The therapeutic target of the ceftibuten and xeruborbactam combination is a dual-enzyme system within Gram-negative Enterobacterales, consisting of penicillin-binding proteins (PBPs) and a broad range of beta-lactamase enzymes (Venatorx Pharmaceuticals, 2024). Ceftibuten, a third-generation cephalosporin, targets PBPs to inhibit the synthesis of the bacterial cell wall, leading to cell death (StatPearls, 2023). However, its efficacy is often compromised by beta-lactamases produced by resistant bacteria. Xeruborbactam is a novel, broad-spectrum cyclic boronate inhibitor designed to target and neutralize these resistance enzymes, including both serine beta-lactamases and metallo-beta-lactamases like New Delhi metallo-beta-lactamase (NDM) (Antimicrobial Agents and Chemotherapy, 2021). By inhibiting these enzymes, xeruborbactam prevents the hydrolysis of ceftibuten, thereby restoring its antibacterial activity against multi-drug resistant pathogens. This combination is particularly significant as it provides a potential oral treatment option for complicated urinary tract infections caused by carbapenem-resistant Enterobacterales (ClinicalTrials.gov, 2024). The dual-targeting approach addresses both the structural integrity of the bacteria and the primary biochemical mechanism of antibiotic resistance.

Other names

PBP3Serine beta-lactamaseMetallo-beta-lactamaseAmbler Class A/B/C/D beta-lactamasesVNRX-7145 targetsCeftibuten-Xeruborbactam targets

Ceftibuten acts by binding to and inhibiting penicillin-binding proteins (PBPs), specifically PBP3, which are essential for the cross-linking of peptidoglycan in the bacterial cell wall (StatPearls, 2023). Xeruborbactam is a broad-spectrum cyclic boronate beta-lactamase inhibitor that protects ceftibuten from degradation by forming a reversible covalent bond with the active-site serine of Class A, C, and D beta-lactamases, or by coordinating with the zinc ions in the active site of Class B metallo-beta-lactamases such as NDM (Venatorx Pharmaceuticals, 2024).